Related Experiment Video
Updated: Aug 6, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Evidence for polymorphism in glisentide
1Departamento de Química, sección de Química-Física, Facultad de Ciencias, Universidad de Navarra, 31080, Pamplona, Spain. azornoza@unav.es
International Journal of Pharmaceutics
|September 16, 1999
Summary
The study investigated glisentide polymorphism, identifying four crystalline forms and an amorphous solid. Solvent properties significantly influence glisentide
Area of Science:
- Pharmaceutical Chemistry
- Solid-State Chemistry
Background:
- Understanding drug polymorphism is crucial for pharmaceutical development.
- Glisentide's solid-state properties require thorough characterization for optimal formulation.
Purpose of the Study:
- To investigate the polymorphism of glisentide.
- To identify and characterize different solid forms of glisentide.
- To understand the influence of solvent properties on glisentide polymorphism.
Main Methods:
- Recrystallization from various solvents.
- Thermal analysis: Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA).
- Spectroscopic and Diffraction techniques: X-ray diffraction (XRD) and Infrared (IR) spectroscopy.
- Optical microscopy.
Main Results:
- Three polymorphs (I, II, III) and an amorphous form were prepared.
- A fourth polymorph (IV) was obtained by heating polymorph III.
- Two stoichiometric solvates (carbon tetrachloride and dioxane) were crystallized.
- Solvent polarity and hydrogen bonding ability significantly impact glisentide polymorphism.
- Phase transitions, including polymorph I recrystallization from melted form II and form III-IV transition, were observed.
Conclusions:
- Glisentide exhibits complex polymorphism influenced by crystallization conditions.
- Characterization confirms the existence of multiple distinct solid forms.
- Solvent selection is critical for controlling glisentide's solid-state properties.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...